Signal
CJC-1295 (With DAC) 5 mg
Research Use Only
CJC-1295 with Drug Affinity Complex, a long-acting GHRH analog reference peptide for endocrine signalling research.
Price on Request
In stockInternal Batch
Pending publication
Category
Signal
Certificate of Analysis
Third-party testing in progress
The Certificate of Analysis will be published upon completion.
What Is This Compound?
CJC-1295 with DAC is a growth hormone-releasing hormone analogue carrying a Drug Affinity Complex (DAC) that is reported to extend its circulating half-life in research models.
Scientific Overview
It is studied in relation to GHRH receptor binding, sustained receptor exposure, and pituitary signalling kinetics compared with short-acting GHRH analogues.
Scientific Classification
Long-acting GHRH analogue (DAC-conjugated)
Primary Research Areas
- GHRH receptor signalling
- Peptide half-life and conjugation research
- Pituitary somatotroph biology
- Endocrine signalling kinetics
Biological Pathway or Mechanism
Investigated within the hypothalamic-pituitary GHRH axis, with research attention on albumin-binding DAC conjugation and prolonged receptor engagement in laboratory models.
Research Status
Investigational GHRH analogue. Not an approved medicine; laboratory research use only.
Scientific descriptions are provided in English to preserve accurate terminology.
Product Specifications
COA & Batch Documentation
Lot Number:
The Certificate of Analysis will be published upon completion.
This Certificate of Analysis applies only to the tested sample and the lot identified in the original laboratory document. It must not be interpreted as applying to another product, strength, lot, or batch.
Potential Benefits
The information below is provided for educational and scientific discussion purposes only. It summarizes research areas that have been explored in laboratory, preclinical, or published scientific research. It is not medical advice and must not be interpreted as evidence of safety, effectiveness, or suitability for human use.
- Studied in laboratory research involving GHRH receptor signalling
- Investigated in preclinical research related to pituitary somatotroph signalling
- Explored in published research concerning peptide conjugation and half-life research
- Examined in laboratory models of endocrine signalling kinetics in vitro
FDA Disclaimer
† These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Research Disclaimer — Research Use Only
This information is provided for general scientific and educational purposes. The product is not intended for human consumption, diagnosis, treatment, prescribing, administration, or dosing. References to approved medicines do not mean that this research product is equivalent to an approved pharmaceutical product.
